Advances of the MAPK pathway in the treatment of spinal cord injury
Shixue Huang,Yinuo Zhang,Haoming Shu,Wei Liu,Xin Zhou,Xuhui Zhou
DOI: https://doi.org/10.1111/cns.14807
2024-06-19
CNS Neuroscience & Therapeutics
Abstract:The activation of MAPK pathway promotes neuroinflammation, neuropathic pain, and neuronal apoptosis. Molecular biology experiments targeting this pathway primarily revolve around drug interventions, stem cell transplantation, and other aspects. Additionally, clinical trials related to this area are progressing vigorously. Spinal cord injury (SCI) represents a complex pathology within the central nervous system (CNS), leading to severe sensory and motor impairments. It activates various signaling pathways, notably the mitogen‐activated protein kinase (MAPK) pathway. Present treatment approaches primarily focus on symptomatic relief, lacking efficacy in addressing the underlying pathophysiological mechanisms. Emerging research underscores the significance of the MAPK pathway in neuronal differentiation, growth, survival, axonal regeneration, and inflammatory responses post‐SCI. Modulating this pathway post‐injury has shown promise in attenuating inflammation, minimizing apoptosis, alleviating neuropathic pain, and fostering neural regeneration. Given its pivotal role, the MAPK pathway emerges as a potential therapeutic target in SCI management. This review synthesizes current knowledge on SCI pathology, delineates the MAPK pathway's characteristics, and explores its dual roles in SCI pathology and therapeutic interventions. Furthermore, it addresses the existing challenges in MAPK research in the context of SCI, proposing solutions to overcome these hurdles. Our aim is to offer a comprehensive reference for future research on the MAPK pathway and SCI, laying the groundwork for targeted therapeutic strategies.
pharmacology & pharmacy,neurosciences